How much funding has OnCusp Therapeutics raised?

OnCusp Therapeutics has raised $125.0M in total funding, most recently a Series A round.

Who are OnCusp Therapeutics's investors?

OnCusp Therapeutics's investors include OrbiMed, F-Prime Capital, Novo Holdings A/S, Sequoia Capital, BioTrack Capital, Oriza Seed Fund.

When was OnCusp Therapeutics founded?

OnCusp Therapeutics was founded in 2021.

Where is OnCusp Therapeutics headquartered?

OnCusp Therapeutics is headquartered in Princeton, New Jersey, United States.

What industry is OnCusp Therapeutics in?

OnCusp Therapeutics operates in Biotech, Healthcare, Therapeutics.

How many employees does OnCusp Therapeutics have?

OnCusp Therapeutics has 11-50 employees.

OnCusp Therapeutics

Princeton, United States · Founded 2021 · $125.0M raised

Biotech

Healthcare

Therapeutics

Headquarters: Princeton, New Jersey
Employees: 11–50
Founded: 2021
Business Model: B2B

Website: oncusptx.com
Total Funding: $125.0M
Last Round: $100.0M Series AJan 2024
Rounds: 2

About

OnCusp Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class oncology therapies, including antibody-drug conjugates (ADCs) and other targeted cancer treatments. Co-founded in 2021 by veterans from Merck, Novartis, and Daiichi Sankyo, the company advanced its lead asset CUSP06 — a CDH6-targeted ADC — into Phase 1 clinical trials and has raised $139M from investors including Novo Holdings and OrbiMed.

Summary

OnCusp Therapeutics is a Biotech company based in Princeton, United States, founded in 2021. It has raised $125.0M in total across 2 rounds, most recently a $100.0M Series A round in Jan 2024. Investors include OrbiMed, F-Prime Capital and Novo Holdings A/S.